Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Accounts Payables: 2020-2025

Historic Accounts Payables for Mereo BioPharma Group (MREO) over the last 2 years, with Sep 2025 value amounting to $879,000.

  • Mereo BioPharma Group's Accounts Payables fell 49.71% to $879,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $879,000, marking a year-over-year decrease of 49.71%. This contributed to the annual value of $2.4 million for FY2024, which is 4.01% up from last year.
  • Mereo BioPharma Group's Accounts Payables amounted to $879,000 in Q3 2025, which was down 22.76% from $1.1 million recorded in Q2 2025.
  • Mereo BioPharma Group's 5-year Accounts Payables high stood at $3.6 million for Q2 2022, and its period low was $879,000 during Q3 2025.
  • In the last 3 years, Mereo BioPharma Group's Accounts Payables had a median value of $2.4 million in 2023 and averaged $2.1 million.
  • Examining YoY changes over the last 5 years, Mereo BioPharma Group's Accounts Payables showed a top increase of 19.10% in 2025 and a maximum decrease of 57.85% in 2025.
  • Over the past 5 years, Mereo BioPharma Group's Accounts Payables (Quarterly) stood at $3.4 million in 2021, then increased by 3.66% to $3.5 million in 2022, then tumbled by 32.82% to $2.3 million in 2023, then rose by 4.01% to $2.4 million in 2024, then crashed by 49.71% to $879,000 in 2025.
  • Its Accounts Payables was $879,000 in Q3 2025, compared to $1.1 million in Q2 2025 and $2.9 million in Q1 2025.